Vertex Pharma (VRTX) Tops Q2 EPS by 19c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus
Tweet Send to a Friend
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $1.26, $0.19 better than the analyst estimate of $1.07. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
